Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.57 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 7/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765918 | 1.00 | CARM1 (0.57) | CARM1PRMT6BCHEMAOBMEN1 | |
| Hydrochloric Acid SCHEMBL7220569 | 0.99 | MEN1 (0.58) | CARM1PRMT6BCHEMAOBMEN1 | |
| Hydrochloric Acid SCHEMBL7220561 | 0.99 | MEN1 (0.58) | CARM1PRMT6BCHEMAOBMEN1 | |
| SCHEMBL8550490 | 0.92 | BCHE (0.65) | CARM1PRMT6BCHEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8556315 | 0.90 | MEN1 (0.65) | CARM1PRMT6BCHEMEN1KMT2A | |
| SCHEMBL250507 | 0.87 | BCHE (0.61) | BCHEMAOBMEN1KMT2AOPRK1 | |
| SCHEMBL2893650 | 0.84 | BCHE (0.60) | BCHEMAOBACHE | |
| SCHEMBL3206960 | 0.84 | BCHE (0.60) | BCHEMAOBACHE | |
| SCHEMBL9685669 | 0.84 | BCHE (0.60) | BCHEMAOBACHE | |
| SCHEMBL22721874 | 0.84 | BCHE (0.58) | BCHEMAOBOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463282-B1 | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | NOVARTIS AG (CH) | 2013-08-07 | — | — | EP | disclosed |
| US-8440682-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8420641-B2 | Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20120264773-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120208816-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2463282-A1 | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-8193349-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| EP-2207775-B1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2404901-A1 | 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2229356-B1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| EP-2207775-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | Novartis Ag (CH) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264773-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CARM1 801/4885PRMT6 409/4885BCHE 968/4885 |
| US-20090118287-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CARM1 801/4885PRMT6 409/4885BCHE 968/4885 |
| US-20120208816-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CARM1 801/4885PRMT6 409/4885BCHE 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.